Fubotv earnings beat by $0.10, revenue topped estimates
Investing.com - Mizuho (NYSE:MFG) raised its price target on Livanova (NASDAQ:LIVN) to $65.00 from $55.00 on Thursday, while maintaining an Outperform rating on the medical technology company’s stock. The company’s shares have already shown strong momentum, posting a 12.25% gain over the past week. According to InvestingPro analysis, LivaNova appears undervalued at current levels, with additional upside potential.
The price target increase follows Livanova’s strong quarterly performance, which included a $20 million revenue beat and earnings that exceeded expectations by $0.18 per share. Mizuho attributed the outperformance to continued momentum in the company’s Cardiopulmonary segment, driven by the Essenz HLM launch across Europe. The company maintains a healthy gross profit margin of 69.45% and operates with a moderate debt level, as highlighted by InvestingPro’s financial health assessment.
Livanova also reported quarter-over-quarter improvement in U.S. Epilepsy volumes despite ongoing challenges related to a field action safety notice. The company raised its full-year revenue guidance to 8-9% growth from the previous 6-7% forecast.
The improved outlook is supported by higher expectations for the Cardiopulmonary segment, now projected to grow 12-13% versus the prior 9-10% estimate, and the Epilepsy segment, revised to 4.5-5.5% growth from 4-5% previously.
Mizuho highlighted several positive catalysts ahead, including favorable real-world results from the VNS Epilepsy study, a national coverage reconsideration for Depression treatment, and potential details about Sleep Apnea launch plans at the December analyst day. Analysts maintain a strong bullish consensus on the stock, with price targets ranging from $53 to $80. For deeper insights into LivaNova’s financial health and growth prospects, including exclusive ProTips and comprehensive valuation metrics, check out the detailed Pro Research Report available on InvestingPro.
In other recent news, LivaNova PLC reported second-quarter 2025 results that exceeded analyst expectations. The company announced adjusted earnings per share of $1.05, surpassing the consensus estimate of $0.87. Revenue for the quarter reached $352.5 million, which was above the anticipated $332.21 million, marking a 10.7% increase compared to the same period last year. On an organic basis, revenue saw a growth of 10.3%. Additionally, LivaNova raised its full-year guidance, reflecting strong performance across its business segments. These developments highlight the company’s robust financial health and operational efficiency. Investors may find these results encouraging as they consider their investment strategies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.